Ebola Vaccine Shows Cross-Protective T Cell Response Against Bundibugyo Virus
Source Summary
Research demonstrates that the Ebola vaccine induces T cell cross-reactivity against Bundibugyo virus (BDBV) in humans. The current BDBV outbreak in the Democratic Republic of the Congo is the second largest Ebola outbreak globally, with over 6,000 confirmed cases and a 48% fatality rate. No approved BDBV vaccine currently exists.
Why it matters
The finding suggests existing Ebola vaccines may provide partial protection against Bundibugyo virus, which is critical given the ongoing outbreak with no approved vaccine and a high fatality rate.
